Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy - Scher, Howard I; Fizazi, Karim; Saad, Fred; Taplin, Mary-Ellen; Sternberg, Cora N; Miller, Kurt; de Wit, Ronald; Mulders, Peter; Chi, Kim N; Shore, Neal D; Armstrong, Andrew J; Flaig, Thomas W; et al. (The New England journal of medicine, 2012)
Keywords: Aged; Androgen Receptor Antagonists - adverse effects; Androgen Receptor Antagonists - therapeutic use; Androgen receptors; Androgens; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Castration; Chemotherapy; Clinical trials; Diarrhea; Disease-Free Survival; Docetaxel; Double-Blind Method; Fatigue; General aspects; Gynecology. Andrology. Obstetrics; Humans; Kaplan-Meier Estimate; Male; Male genital diseases; Medical sciences; Men; Metastases; Middle Aged; Multivariate Analysis; Neoplasm Metastasis - drug therapy; Nephrology. Urinary tract diseases; Orchiectomy; Pain; Phenylthiohydantoin - adverse effects; Phenylthiohydantoin - analogs & derivatives; Phenylthiohydantoin - therapeutic use; Prostate cancer; Prostate-specific antigen; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - mortality; Prostatic Neoplasms - surgery; Seizures; Seizures - chemically induced; Signal transduction; Signal Transduction - drug effects; Survival; Taxoids - therapeutic use; Testosterone; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Medicine; Chemotherapy; Urinary system disease; Treatment; Prostate disease; Malignant tumor; Male genital diseases; Prostate cancer; Survival; Cancer